RBC's Brian Abrahams holds a mock adcomm on Biogen's iffy aducanumab data — and most of these experts don't see a path to an approval
As catalysts go, few loom larger than the aducanumab adcomm slated for Nov. 6.
With its big franchise under assault, Biogen is betting …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
